



## ASX Announcement

2 May 2023

### OPYL APPOINTS GLOBAL CLINICAL TRIAL AND HEALTH TECH EXPERT, DR. HUGO STEPHENSON, AS BOARD ADVISOR

**Melbourne, Australia – Opyl Limited (ASX:OPL, or the “Company”)** is pleased to announce that it has engaged leading global clinical trial expert and eminent business leader in the health technology sector, Dr. Hugo Stephenson, as an advisor to the board.

His appointment is an important development in the Company's strategic review, which focuses on accelerating the growth of OpIn and monetising the TrialKey technology platform.

Dr. Stephenson is a medical doctor, technologist, biotech services entrepreneur and founder of a number of successful businesses in the international clinical trials industry, including:

- **DrugDev**, a leading provider of e-clinical technologies and clinical trial payment services;
- **MediGuard**, the largest online medication monitoring service;
- **Health Research Solutions (HRS)**, a late phase contract research organisation; and
- **MedSeed**, a pioneer of hospital and GP decision support software.

Dr. Stephenson worked for many years as the founder of **Quintiles'** global late phase research division (now **IQVIA**) following the acquisition of HRS, and has considerable experience managing organisations within both a public market and private equity-backed environment.

He is also the founder and past Chief Executive Officer of the **Induction Healthcare Group PLC** (AIM:INHC), a leading developer of digital care tools for healthcare systems in the UK and Ireland.

“The clinical trial sector is ripe for disruption and the technologies that Opyl is bringing to the global stage, including the use of AI, have the potential to change the way clinical trials are undertaken around the world,” said Dr. Stephenson.

“I believe that OpIn and TrialKey offerings are unique, if not revolutionary. I am excited to be assisting Opyl at this exciting stage of its Opyl growth story, as it looks to expand its offerings and scale the business globally.”

Michelle Gallaher, Opyl's Chief Executive Officer, commented:



"I am delighted to welcome Dr. Stephenson to the Opyl team and to have this opportunity to work with someone of his standing as Opyl has never been in a better position to significantly improve clinical trial outcomes.

"We will benefit greatly from Dr. Stephenson's international experience and expertise, particularly in honing our go-to-market strategy, expanding our organic and inorganic growth options, and further developing our global networks."

The Board has authorised this announcement for release to the ASX.

**-ENDS-**

**For media and investor enquiries:**

E: [info@opyl.a](mailto:info@opyl.a)

[www.opyl.ai](http://www.opyl.ai)

**For clinical trial recruitment enquiries:**

E: [info@opyl.a](mailto:info@opyl.a)

[www.opin.ai](http://www.opin.ai)

**About Opyl Limited**

Opyl is a new generation Australian digital health company that applies artificial intelligence to improving clinical trials. Our platforms make clinical trials more efficient and easier to access, giving patients more options and saving medical researchers time and money.

Our key offering for biopharma, medtech, government and healthcare organisations:

- clinical trial recruitment solutions – Opin.ai
- clinical trial predictive analytics and protocol design – TrialKey
- deep social media insights and analysis – Social Insights

Follow Opyl on:

